Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
about
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaSensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Liquid biomarkers in melanoma: detection and discovery.Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.Impact of genomics on the surgical management of melanoma.Emerging biomarkers for cancer immunotherapy in melanoma.Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingPromising clinical application of ctDNA in evaluating immunotherapy efficacy
P2860
Q42362520-02EFE052-BAD5-4FC2-BACE-DCF44226DC9FQ43274590-A547435B-C8BF-4728-97BF-492953C0F460Q47139923-65BA2E68-A5B7-47BE-A22F-0CC44FDA8970Q47563363-376A5801-000E-4A1A-A3F3-A72BB63E06FCQ47726847-D5B2D2C2-3116-4395-AF58-3EC8AD015A50Q49317428-E66A3783-505E-4C53-81A0-68B5197A9B81Q49914126-B02443E4-F36F-4804-978B-46FA18C62DC3Q50010320-F54699F3-23A3-4026-9403-9B76EDBC53FDQ50058145-AE375195-1CDA-430B-BA95-6D287E7F7316Q50059462-524A4E4F-CF75-49F6-A051-97AB833572A1Q50104370-895911EE-8DE1-48E7-8947-17D9C92C292BQ54960920-8031CFB1-333B-49EB-A323-FC21B7DFD162Q55016615-3F2A9844-7FC3-4B42-856C-5ED3DE5B559DQ55536917-44B0A696-2246-4607-BB0E-006FD7543BB7Q55709201-904FF8C0-AC35-4058-9411-E09680861221Q58757488-7F8D432B-D023-45FC-88D2-F30B481B8BB9Q58790057-CDA0F968-DE24-44CB-9E85-9AE694F83823
P2860
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@en
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@nl
type
label
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@en
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@nl
prefLabel
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@en
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDX026
P50
P577
2017-05-01T00:00:00Z